Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
IL6 elevation
i
Other names:
IL6, BSF2, HGF, HSF, IFNB2, IL-6, Interleukin 6
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3569
Related biomarkers:
Expression
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
IL6 elevation
Melanoma
IL6 elevation
Melanoma
ipilimumab
Resistant: B - Late Trials
ipilimumab
Resistant
:
B
ipilimumab
Resistant: B - Late Trials
ipilimumab
Resistant
:
B
IL6 elevation
Melanoma
IL6 elevation
Melanoma
nivolumab + ipilimumab
Resistant: B - Late Trials
nivolumab + ipilimumab
Resistant
:
B
nivolumab + ipilimumab
Resistant: B - Late Trials
nivolumab + ipilimumab
Resistant
:
B
IL6 elevation
Gastric Cancer
IL6 elevation
Gastric Cancer
nivolumab + ramucirumab
Sensitive: C3 – Early Trials
nivolumab + ramucirumab
Sensitive
:
C3
nivolumab + ramucirumab
Sensitive: C3 – Early Trials
nivolumab + ramucirumab
Sensitive
:
C3
IL6 elevation
Non Small Cell Lung Cancer
IL6 elevation
Non Small Cell Lung Cancer
ABBV-181
Sensitive: C3 – Early Trials
ABBV-181
Sensitive
:
C3
ABBV-181
Sensitive: C3 – Early Trials
ABBV-181
Sensitive
:
C3
IL6 elevation
Cervical Cancer
IL6 elevation
Cervical Cancer
ipilimumab
Resistant: C3 – Early Trials
ipilimumab
Resistant
:
C3
ipilimumab
Resistant: C3 – Early Trials
ipilimumab
Resistant
:
C3
IL6 elevation
Melanoma
IL6 elevation
Melanoma
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
IL6 elevation
Small Cell Lung Cancer
IL6 elevation
Small Cell Lung Cancer
ipilimumab
Resistant: C3 – Early Trials
ipilimumab
Resistant
:
C3
ipilimumab
Resistant: C3 – Early Trials
ipilimumab
Resistant
:
C3
IL6 elevation
Uveal Melanoma
IL6 elevation
Uveal Melanoma
tebentafusp-tebn
Sensitive: C3 – Early Trials
tebentafusp-tebn
Sensitive
:
C3
tebentafusp-tebn
Sensitive: C3 – Early Trials
tebentafusp-tebn
Sensitive
:
C3
IL6 elevation
Renal Cell Carcinoma
IL6 elevation
Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
IL6 elevation
Renal Cell Carcinoma
IL6 elevation
Renal Cell Carcinoma
sunitinib
Resistant: C3 – Early Trials
sunitinib
Resistant
:
C3
sunitinib
Resistant: C3 – Early Trials
sunitinib
Resistant
:
C3
IL6 elevation
Renal Cell Carcinoma
IL6 elevation
Renal Cell Carcinoma
sunitinib + pazopanib
Resistant: C3 – Early Trials
sunitinib + pazopanib
Resistant
:
C3
sunitinib + pazopanib
Resistant: C3 – Early Trials
sunitinib + pazopanib
Resistant
:
C3
IL6 elevation
Clear Cell Renal Cell Carcinoma
IL6 elevation
Clear Cell Renal Cell Carcinoma
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
IL6 elevation
Hepatocellular Cancer
IL6 elevation
Hepatocellular Cancer
bevacizumab + atezolizumab
Resistant: C3 – Early Trials
bevacizumab + atezolizumab
Resistant
:
C3
bevacizumab + atezolizumab
Resistant: C3 – Early Trials
bevacizumab + atezolizumab
Resistant
:
C3
IL6 elevation
Diffuse Large B Cell Lymphoma
IL6 elevation
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Resistant: C3 – Early Trials
axicabtagene ciloleucel
Resistant
:
C3
axicabtagene ciloleucel
Resistant: C3 – Early Trials
axicabtagene ciloleucel
Resistant
:
C3
IL6 elevation
Melanoma
IL6 elevation
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
IL6 elevation
Renal Cell Carcinoma
IL6 elevation
Renal Cell Carcinoma
pembrolizumab + axitinib
Resistant: C3 – Early Trials
pembrolizumab + axitinib
Resistant
:
C3
pembrolizumab + axitinib
Resistant: C3 – Early Trials
pembrolizumab + axitinib
Resistant
:
C3
IL6 elevation
HER2 Positive Breast Cancer
IL6 elevation
HER2 Positive Breast Cancer
trastuzumab
Sensitive: C3 – Early Trials
trastuzumab
Sensitive
:
C3
trastuzumab
Sensitive: C3 – Early Trials
trastuzumab
Sensitive
:
C3
IL6 elevation
Mantle Cell Lymphoma
IL6 elevation
Mantle Cell Lymphoma
TG-1701
Sensitive: D – Preclinical
TG-1701
Sensitive
:
D
TG-1701
Sensitive: D – Preclinical
TG-1701
Sensitive
:
D
IL6 elevation
Mantle Cell Lymphoma
IL6 elevation
Mantle Cell Lymphoma
umbralisib + ublituximab-xiiy + TG-1701
Sensitive: D – Preclinical
umbralisib + ublituximab-xiiy + TG-1701
Sensitive
:
D
umbralisib + ublituximab-xiiy + TG-1701
Sensitive: D – Preclinical
umbralisib + ublituximab-xiiy + TG-1701
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login